Roslyn Bill

Professor of Biotechnology Aston University

  • Birmingham

Professor Bill's research on water flow in the body has revealed how to develop drugs that prevent brain swelling after injury or disease.

Contact

Aston University

View more experts managed by Aston University

View all Experts

Spotlight

5 min

Aston University and Birmingham Women and Children’s Hospital developing new devices to improve drug treatment safety

The new device is designed to reduce the risk of injuries when medicines being delivered into a vein enter the surrounding tissues It detects this problem at the earliest stages, before it is visible to the human eye The project is being supported by SPARK The Midlands at Aston University, a network to support technology development for unmet clinical needs. Clinicians at Birmingham Women’s and Children's NHS Foundation Trust (BWC) have joined with academics at Aston University to create an innovative sensor to reduce the risk of injuries caused when drugs being delivered into a vein enter the surrounding tissue. This complication, called extravasation, can cause harm and, in the most severe cases, life-changing injuries and permanent scarring. It happens most often when infusing medicines into peripheral intravenous (IV) devices, such as a cannula, but can also occur when infusing into a central venous access device. By joining together, BWC and Aston University are combining clinical, academic and engineering expertise to create a sensor that can detect extravasation at its earliest stages. Karl Emms, lead nurse for patient safety at BWC, said: “We've done lots of work across our Trust that has successfully reduced incidents. While we've made fantastic progress, there is only so much we can do as early signs of extravasation can be difficult to detect with the human eye. “The next step is to develop a technology that can do what people can't detection as it happens. This will make a huge impact on outcomes as the faster we can detect extravasation, the less likely it is that it will cause serious harm.” The focused work to date addressing the issue has recently been recognised by the Nursing Times Awards 2024, winning the Patient Safety Improvement title for this year. This new project is supported by SPARK The Midlands, a network at Aston University dedicated to providing academic support to advance healthcare research discoveries in the region. SPARK The Midlands is the first UK branch of Stanford University's prestigious global SPARK programme. It comes as a result of Aston University’s active involvement in the delivery of the West Midlands Health Tech Innovation Accelerator (WMHTIA) – a government-funded project aimed at helping companies drive their innovations towards market success. The SPARK scheme helps to provide mentorship and forge networks between researchers, those with technical and specialist knowledge and potential sources of funding. SPARK members have access to workshops led by industry experts, covering topics such as medical device regulations, establishing good clinical trials, and creating an enticing target product profile to engage future funders. Luke Southan, head of research commercialisation at Aston University and SPARK UK director, said: “I was blown away when Karl first brought this idea to me. I knew we had to do everything we could to make this a reality. This project has the potential to transform the standard of care for a genuine clinical need, which is what SPARK is all about.” Work on another potentially transformative project has also begun as the team are working to develop a medical device that detects the position of a nasogastric feeding tube. There is a risk of serious harm and danger to life if nasogastric tubes move into the lungs, rather than the stomach, and feed is passed through them. Emms explained: “pH test strips can usually detect nasogastric tube misplacement, but some children undergoing treatment can have altered pH levels in the stomach. This means this test sometimes does not work. “A medical device that can detect misplacement can potentially stop harm and fatalities caused by these incidents.” SPARK will bring together engineers, academics and clinicians for both projects to develop the devices for clinical trial, with a goal of the technologies being ready for clinical use in three to five years. Southan said: “BWC is one of our first partners at SPARK and we're really excited to work with them to make a vital impact on paediatric healthcare in the Midlands and beyond." Notes to editors About Aston University For over a century, Aston University’s enduring purpose has been to make our world a better place through education, research and innovation, by enabling our students to succeed in work and life, and by supporting our communities to thrive economically, socially and culturally. Aston University’s history has been intertwined with the history of Birmingham, a remarkable city that once was the heartland of the Industrial Revolution and the manufacturing powerhouse of the world. Born out of the First Industrial Revolution, Aston University has a proud and distinct heritage dating back to our formation as the School of Metallurgy in 1875, the first UK College of Technology in 1951, gaining university status by Royal Charter in 1966, and becoming the Guardian University of the Year in 2020. Building on our outstanding past, we are now defining our place and role in the Fourth Industrial Revolution (and beyond) within a rapidly changing world. For media inquiries in relation to this release, contact Helen Tunnicliffe, Press and Communications Manager, on (+44) 7827 090240 or email: h.tunnicliffe@aston.ac.uk About Birmingham Women’s and Children’s NHS Foundation Trust Birmingham Women’s and Children’s NHS Foundation Trust (BWC) brings together the very best in paediatric and women’s care in the region and is proud to have many UK and world-leading surgeons, doctors, nurses, midwives and other allied healthcare professionals on its team. Birmingham Children’s Hospital is the UK’s leading specialist paediatric centre, caring for sick children and young people between 0 and 16 years of age. Based in the heart of Birmingham city centre, the hospital is a world leader in some of the most advanced treatments, complex surgical procedures and cutting-edge research and development. It is a nationally designated specialist centre for epilepsy surgery and also boasts a paediatric major trauma centre for the West Midlands, a national liver and small bowel transplant centre and a centre of excellence for complex heart conditions, the treatment of burns, cancer and liver and kidney disease. The hospital is also home to one of the largest Child and Adolescent Mental Health Services in the country, comprising of a dedicated inpatient Eating Disorder Unit and Acute Assessment Unit for regional referrals of children and young people with the most serious of problems (Tier 4) and Forward Thinking Birmingham community mental health service for 0to 25-year-olds. Birmingham Women’s Hospital is a centre of excellence, providing a range of specialist health care services to over 50,000 women and their families every year from Birmingham, the West Midlands and beyond. As well as delivering more than 8,200 babies a year, it offers a full range of gynaecological, maternity and neonatal care, as well as a comprehensive genetics service, which serves men and women. Its Fertility Centre is one of the best in the country, while the fetal medicine centre receives regional and national referrals. The hospital is also an international centre for education, research and development with a research budget of over £3 million per year. It also hosts the national miscarriage research centre – the first of its kind in the UK in partnership with Tommy’s baby charity. For interview requests please email the Communications Team on bwc.communications@nhs.net

Roslyn Bill

2 min

Podcast: Aston University researchers discuss how brain injury research led to a better understanding of dementia causes

Professor Roslyn Bill discusses her research into brain cell membranes with Dr Matt Derry Serious brain injuries and dementia are affected by the flow of water through a protein called aquaporin-4 in brain cell membranes Aquaporins are responsible for clearing the build-up of waste products in brain cells in a process Professor Bill likens to a ‘dishwasher for your brain’. Professor Roslyn Bill, co-founder of Aston Institute for Membrane Excellence (AIME), joins Dr Matt Derry to discuss her research into brain cell membranes in the latest Aston Originals podcast. Water moves in and out of brain cells through tiny protein channels in the cell membrane called aquaporins. One in particular, aquaporin-4, is the focus of Professor Bill’s research. In 2020, she was lead author on a paper published in prestigious journal Cell on how the channels open and close and how this can be controlled. Uncontrolled water entry into brain cells can occur after head trauma, causing swelling which leads to severe brain injuries of the type suffered by racing driver Michael Schumacher after a skiing accident. Finding drugs to control this water movement could lead to treatments to prevent brain swelling in the first place. This research into brain swelling and the contribution of aquaporins led Professor Bill to research into Alzheimer’s, a common form of dementia, which is also related to the action of aquaporins. Alzheimer’s is caused by a build-up of waste products in brain cells. In a process Professor Bill likened to a ‘dishwasher for your brain’, aquaporins are responsible for clearing this waste as we sleep. Professor Bill was selected for an Advanced Grant by the European Research Council (ERC) in 2023, which is being funded by UK Research and Innovation (UKRI). The funded project will further investigate the process, and whether it might be possible to develop a drug to boost the ‘brain dishwasher’, which could be taken to slow or even prevent cognitive decline due to ageing. Bringing together this biological research with the polymer research of AIME, chemists like Dr Derry will help in the drug development and could also lead to totally different applications. Professor Bill said in the podcast to Dr Derry: “We can take the knowledge that we have of how these proteins work in cells and try and apply them to interesting applications in biotechnology. And this is where the sort of work that you (Dr Derry) do comes in, where you can develop plastic membranes, polymer membranes, and then take learning from the biology and try and make really, really good ways of purifying water, for example.” For more information about AIME, visit the webpage. The website also includes links to the previous AIME podcast and details about open positions.

Roslyn BillDr Matthew Derry

5 min

Aston University receives £10m from Research England to establish the Aston Institute for Membrane Excellence

Image shows how tiny water channels control how water enters and exits cells through their membranes The Aston Institute for Membrane Excellence (AIME) will be set up with a £10m grant from Research England AIME will be led by Professor Roslyn Bill from Biosciences and Professor Paul Topham from Chemical Engineering and Applied Chemistry The globally unique institute will use biomimetic polymer membranes for applications such as water purification and drug development Aston University will establish the Aston Institute for Membrane Excellence (AIME), a globally unique, cross-disciplinary institute to develop novel biomimetic membranes, after receiving a major grant of £10m from Research England. AIME will be led by Professor Roslyn Bill, from the School of Biosciences, with co-lead Professor Paul Topham from the department of Chemical Engineering and Applied Chemistry (CEAC). Membranes, both biological and synthetic, are hugely important in many sectors. For example, the world’s top ten selling human medicines all target proteins in biological membranes, while synthetic polymer membranes are used in the US$100bn/year water purification industry. The team behind AIME believes that the full potential of membranes will only be realised by an interdisciplinary group spanning biology, physics and chemistry that can investigate membranes holistically. Professor Bill, a European Research Council (ERC) Advanced grantee leads Aston Membrane Proteins and Lipids (AMPL) research centre of excellence that studies the structure and function of membrane proteins and associated lipids. Professor Topham leads Aston Polymer Research Group (APRG), which investigates the nanoscale behaviour of block copolymers (a type of polymer with a structure made of more than one type of polymer molecule) and polymer technologies for membranes. AMPL and APRG have already begun collaborative research and AIME will bring together the complementary expertise of both research clusters into one institute. AIME will initially comprise the eight researchers from AMPL and APRG. Alongside the co-leads Professor Bill and Professor Topham, will be Dr Alan Goddard, Professor Andrew Devitt, Professor Corinne Spickett, Dr Alice Rothnie, Dr Matt Derry and Dr Alfred Fernandez. It plans to recruit three further academics, six tenure-track research fellows, three postdoctoral research assistants (PDRAs), six PhD students, a research technician and a business development manager. Importantly, AIME will work with many existing Aston University colleagues to build a comprehensive research community focused on all aspects of membrane science. The new AIME team will focus on the development of bioinspired, highly selective polymer structures for applications in water purification and waste remediation, nanoparticles loaded with therapeutic molecules to treat disorders ranging from chronic wounds to neurological injuries, and the purification of individual membrane proteins with polymers to study them as drug targets. The vision is for AIME to become a ‘one-stop shop’ for interdisciplinary, translational membrane research through its facilities access and expertise, ideally located in the heart of the country. Professor Bill said: “The creation of AIME is ground-breaking. Together with Aston’s investment, E3 funding will deliver a step-change in scale and the rate at which we can grow capacity. We will address intractable scientific challenges in health, disease, and biotechnology, combining our world-class expertise in polymer chemistry and membrane biology to study membranes holistically. The excellence of our science, alongside recent growth in collaborative successes means we have a unique opportunity to deliver AIME’s ambitious and inclusive vision.” Professor Topham said: “We are really excited by this fantastic opportunity to work more closely with our expert colleagues in Biosciences to create advanced technology to address real world problems. From our side, we are interested in molecular engineering, where we control the molecular structure of new materials to manipulate their properties to do the things that we want! Moreover, we are passionate about a fully sustainable future for our planet, and this investment will enable us to develop technological solutions in a sustainable or ‘green’ way.” Professor Aleks Subic, Vice-Chancellor and Chief Executive of Aston University, says: “Our new Aston Institute for Membrane Excellence (AIME) will be a regional, national, and international research leader in membrane science, driving game-changing research and innovation that will produce a pipeline of high-quality research outcomes leading to socioeconomic impact, develop future global research leaders, create advanced tech spinout companies and high value-added jobs for Birmingham and the West Midlands region. Its establishment aligns perfectly with our 2030 strategy that positions Aston University as a leading university of science, technology and enterprise.” Steven Heales, Policy Manager (Innovation) at the West Midlands Combined Authority, said: “WMCA is delighted to see Research England back the Aston Institute for Membrane Excellence. This will enable Aston University’s excellent academics and research community to work closely with businesses to make advances in membrane technology and applications. “In 2023 the West Midlands Combined Authority agreed a Deeper Devolution Trailblazer Deal with Government, which included a new strategic innovation partnership with Government. Projects like AIME are exactly the kind of impact we expect this new partnership to generate, so watch this space.” Lisa Smith, chief executive of Midlands Mindforge, the patient capital investment company formed by eight Midlands research-intensive universities including Aston University, said: “This grant is an important vote of confidence in the Midlands scientific R&D ecosystem. AIME will play an important role in the future research of pioneering breakthroughs in membrane science and enable the world-leading research team at Aston University to develop solutions to real world problems. We look forward to closely working with the Institute and nurturing best-in-field research being undertaken at Aston out of the lab and into the wider society so it can make a positive impact”. Rob Valentine, regional director of Bruntwood SciTech, the UK’s leading developer of city-wide innovation ecosystems and specialist environments and a strategic partner in Birmingham Innovation Quarter, said: "As a proud supporter of the Aston Institute for Membrane Excellence (AIME), I am thrilled at the launch of this groundbreaking initiative. AIME exemplifies Aston University's commitment to advancing cutting-edge interdisciplinary research and further raises the profile of the region’s exemplary research capabilities and sector specialisms. AIME's vision of becoming a 'one-stop shop' for translational membrane research, strategically located at the heart of the country, aligns perfectly with our strategy at Bruntwood SciTech. We are committed to working with partners, including Aston University, to develop a globally significant innovation district at the heart of the UK where the brightest minds and most inspiring spaces will foster tomorrow’s innovation.” Membrane research at Aston University has also recently received two other grants. In November 2023, Professor Bill received £196,648 from the Biotechnology and Biological Sciences Research Council’s Pioneer Awards Scheme to understand how tiny membrane water channels in brain cells keep brains healthy. In December 2023, a team led by AIME team-member Dr Derry received £165,999 from the Engineering and Physical Sciences Research Council to develop biomimetic membranes for water purification. For more information about AIME, visit the webpage.

Roslyn BillPaul TophamDr Matthew DerryDr Alan GoddardAndrew Devitt
Show More +

Media

Social

Biography

Membrane proteins are the targets of over half of all prescription pharmaceuticals. I am an international authority on the synthesis and characterization of membrane proteins for biochemical, biophysical and structural analysis, which is the basis of modern drug discovery. My scientific focus is on aquaporin water channels (AQP), G protein-coupled receptors and tetraspanins.

In 2009, I led the multidisciplinary team that discovered a novel pathway that controls the permeability of cells to water. I have published a suite of articles describing this regulatory mechanism for human AQP1, 3, 4 and 5. These findings provide the foundation of understanding the mechanistic basis of water imbalance.

After a stroke or a traumatic head injury, the brain swells. This affects tens of millions of people every year. This swelling, known as ‘cytotoxic oedema’, can lead to death, disability and an increased risk of neurodegeneration with ageing. This is what happened to Michael Schumacher after his skiing accident in 2013. Current clinical treatments are crude and limited to symptom management. They include removal of part of the skull to allow the brain space to swell or the use of chemicals to draw water out of the brain tissue; these treatments are risky, especially for older patients. My team has discovered how water enters the brain and how to stop this happening after an injury. This means we can develop medicines to stop cytotoxic oedema developing and therefore reduce the need for life-threatening surgery. Excitingly, we have identified a compound that is already licenced in humans for another purpose. I am actively working towards testing whether it can be used as an anti-cytotoxic oedema medicine in a clinical trial.

Areas of Expertise

Membrane Proteins
Brain Swelling
Water Balance
Healthy Ageing
Brain Injury

Education

University of Oxford

DPhil

1994

Wellcome Trust Prize Student

University of Oxford

MA

Natural Science (Chemistry)

1993

University of Oxford

BA

Natural Science (Chemistry)

1990

Affiliations

  • BBSRC Research Committee E: Chair
  • Biotechnology Letters : Editorial Board Member
  • Molecular Biotechnology : Editorial Board Member
  • BBA-Biomembranes : Editorial Board Member
  • Membranes : Editorial Board Member
Show All +

Media Appearances

Michael Schumacher: Miracle treatment gives 'full recovery' hope for brain injury patients

Expres  online

2020-06-11

Professor Roslyn Bill of the Biosciences Research Group at Aston University said: "Every year, millions of people of all ages suffer brain and spinal injuries, whether from falls, accidents, road traffic collisions, sports injuries or stroke.

View More

Study uncovers new applications for schizophrenia drug

BBC  online

2020-05-15

"Rats who had not been given the treatment were still disabled after six weeks, but those who had a single injection, can walk normally after just two weeks," lead scientist Prof Roslyn Bill, at Aston University, said.

View More

'Cell pores' discovery gives hope to millions of brain and spinal cord injury patients

University of Birmingham  online

2020-05-14

Professor Roslyn Bill of the Biosciences Research Group at Aston University said: “Every year, millions of people of all ages suffer brain and spinal injuries, whether from falls, accidents, road traffic collisions, sports injuries or stroke. To date, their treatment options have been very limited and, in many cases, very risky.

View More

Show All +

Articles

Purification and immobilization of engineered glucose dehydrogenase: a new approach to producing gluconic acid from breadwaste

Biotechnology for Biofuels

2020

Platform chemicals are essential to industrial processes. Used as starting materials for the manufacture of diverse products, their cheap availability and efficient sourcing are an industrial requirement. Increasing concerns about the depletion of natural resources and growing environmental consciousness have led to a focus on the economics and ecological viability of bio-based platform chemical production. Contemporary approaches include the use of immobilized enzymes that can be harnessed to produce high-value chemicals from waste.

View more

Expression of eukaryotic membrane proteins in eukaryotic and prokaryotic hosts

Methods

2020

The production of membrane proteins of high purity and in satisfactory yields is crucial for biomedical research. Due to their involvement in various cellular processes, membrane proteins have increasingly become some of the most important drug targets in modern times. Therefore, their structural and functional characterization is a high priority. However, protein expression has always been more challenging for membrane proteins than for soluble proteins.

View more

Targeting Aquaporin-4 Subcellular Localization to Treat Central Nervous System Edema

Cell

2020

Swelling of the brain or spinal cord (CNS edema) affects millions of people every year. All potential pharmacological interventions have failed in clinical trials, meaning that symptom management is the only treatment option. The water channel protein aquaporin-4 (AQP4) is expressed in astrocytes and mediates water flux across the blood-brain and blood-spinal cord barriers.

View more

Show All +
Powered by